Table 1.
TAMs targeting therapies.
| Target site | Substance | Cancer type | Mechanism of action | Phase |
|---|---|---|---|---|
| CCL2/CCR2 axis | Carlumab (CNTO 888) | Prostate cancer | Suppress the expression of CCL2 | II |
| CCL2/CCR2 axis | PF-04136309 | Pancreatic cancer | Blockade of CCR2 | Ib |
| CSF-1/CSF-1R | Emactuzumab | Solid tumors | Blockade of CSF-1R | I |
| CSF-1/CSF-1R | AMG-820 | Solid tumors | Blockade of CSF-1R | I |
| CSF-1/CSF-1R | Pexidartinib | Tenosynovial giant cell tumor | Blockade of CSF-1R | III |
| CD47 and SIRP-a | Bromonitrozidine (RRx-001) | Colorectal cancer | Macrophage repolarizing | II |
| NA | Zoledronic acid | Breast cancer | Depletion of M2-like TAMs | III |